Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 5:24 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 13,764 matching trials from the live ClinicalTrials.gov search.
Filters: Dallas, Texas Clear all
Completed Phase 2 Interventional

Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR)

NCT06176196
View directory record Official record
Conditions
Painful Lumbosacral Radiculopathy
Interventions
VX-548, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
54
States / cities
Phoenix, Arizona • Bakersfield, California • Banning, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Nov 3, 2026, 5:24 AM EST
Recruiting No phase listed Observational

Cool Prime Comparative Effectiveness Study for Mild HIE

NCT04621279
View directory record Official record
Conditions
Mild Hypoxic Ischemic Encephalopathy of Newborn
Interventions
Normothermia, Whole body therapeutic hypothermia
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
36 Weeks and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 3, 2026, 5:24 AM EST
Recruiting Not applicable Interventional

Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation

NCT07387796
View directory record Official record
Conditions
Drug Discontinuation, Substance Use Disorders, Eating Behavior Changes, Tirzepatide
Interventions
Discontinuation and Reinitiation of Tirzepatide
Other
Lead sponsor
The University of Texas at Dallas
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Nov 3, 2026, 5:24 AM EST
Active, not recruiting Not applicable Interventional

A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy

NCT06414603
View directory record Official record
Conditions
Heart Transplant Failure and Rejection
Interventions
The Prospera™ Test
Diagnostic Test
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 3, 2026, 5:24 AM EST
Completed Phase 3 Interventional

A Study of Lebrikizumab in Participants With Uncontrolled Asthma on Inhaled Corticosteroids and a Second Controller Medication

NCT01868061
View directory record Official record
Conditions
Asthma
Interventions
Lebrikizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,068 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
66
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Nov 3, 2026, 5:24 AM EST
Completed Phase 2 Interventional

S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma

NCT00005089
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2014
U.S. locations
92
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Nov 3, 2026, 5:24 AM EST
Not listed No phase listed Observational

Reiterative Development and Evaluation Study of OSA Therapy System

NCT01634074
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Not listed
Lead sponsor
ApniCure, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
7
States / cities
Burlingame, California • Redwood City, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Nov 3, 2026, 5:24 AM EST
Recruiting Not applicable Interventional

ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve

NCT05172960
View directory record Official record
Conditions
Aortic Stenosis, Severe
Interventions
SAPIEN X4 THV, SAPIEN X4S
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
1,234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2037
U.S. locations
58
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 3, 2026, 5:24 AM EST
Completed Phase 2 Interventional Results available

Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis

NCT01710046
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
(CP-6890,550) Tofacitinib, Placebo, (CP-690,550) Tofacitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
5
States / cities
Los Angeles, California • Tampa, Florida • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Nov 3, 2026, 5:24 AM EST
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

NCT01952574
View directory record Official record
Conditions
Migraine
Interventions
Erenumab, Placebo, Erenumab PFS, Erenumab AI/Pen
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
41
States / cities
Phoenix, Arizona • Long Beach, California • National City, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Nov 3, 2026, 5:24 AM EST
Recruiting Phase 3 Interventional

Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)

NCT07100990
View directory record Official record
Conditions
Optic Neuritis, Myelitis, Myelitis, Transverse
Interventions
High-dose corticosteroids (HDCS), High-dose corticosteroids (HDCS) and PLEX
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Loma Linda, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 3, 2026, 5:24 AM EST
Recruiting Phase 2 Interventional

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

NCT06619860
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
VX-993, Pregabalin, Placebo (matched to pregabalin), Placebo (matched to VX-993)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
25
States / cities
Cullman, Alabama • Bakersfield, California • La Mesa, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Nov 3, 2026, 5:24 AM EST
Active, not recruiting No phase listed Observational

Prospective Study of Pregnancy in Women With Cystic Fibrosis

NCT04828382
View directory record Official record
Conditions
Pregnancy Related, Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Amalia Magaret
Other
Eligibility
16 Years and older · Female only
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
40
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Nov 3, 2026, 5:24 AM EST
Completed Phase 2 Interventional

A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer

NCT00245362
View directory record Official record
Conditions
Metastatic Pancreatic Cancer, Nonresectable Pancreatic Cancer
Interventions
CG 8020 and CG 2505
Biological
Lead sponsor
Cell Genesys
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
2
States / cities
Baltimore, Maryland • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2005 · Synced Nov 3, 2026, 5:24 AM EST
Withdrawn No phase listed Observational

ORACLE-NIRS: Lipid cORe Plaque Association With CLinical Events: a Near-InfraRed Spectroscopy Study

NCT02265146
View directory record Official record
Conditions
Coronary Atherosclerosis
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
5
States / cities
Gainesville, Florida • Atlanta, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Nov 3, 2026, 5:24 AM EST
Completed Not applicable Interventional Results available

Bracing for Walking in Parkinson's Disease

NCT03192046
View directory record Official record
Conditions
Gait Disorders, Neurologic, Parkinson Disease
Interventions
Carbon Fiber Ankle Foot Orthosis (AFO), Standardized walking/exercise program
Device · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
30 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Nov 3, 2026, 5:24 AM EST
Completed Phase 4 Interventional Results available

An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers

NCT02869789
View directory record Official record
Conditions
Lung Cancer
Interventions
Nivolumab in combination with Ipilimumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,041 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Nov 3, 2026, 5:24 AM EST
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma

NCT00006760
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, ifosfamide, vinorelbine tartrate
Biological · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
101
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 90 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2013 · Synced Nov 3, 2026, 5:24 AM EST
Terminated Phase 3 Interventional

Stage IV Surgery Versus Best Medical Therapy

NCT01013623
View directory record Official record
Conditions
Stage IV Resectable Melanoma
Interventions
Surgery, Surgery plus 2 adjuvant doses of BCG, best medical therapy
Procedure · Other
Lead sponsor
Saint John's Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
15
States / cities
Sacramento, California • Santa Monica, California • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2012 · Synced Nov 3, 2026, 5:24 AM EST
Completed No phase listed Observational

Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM)

NCT02997423
View directory record Official record
Conditions
Glioblastoma
Interventions
Not listed
Lead sponsor
University of Iowa
Other
Eligibility
21 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
19
States / cities
Birmingham, Alabama • Sacramento, California • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Nov 3, 2026, 5:24 AM EST
Completed Phase 2 Interventional Results available

An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers

NCT03662659
View directory record Official record
Conditions
Gastric Cancer, Cancer of the Stomach, Esophagogastric Junction
Interventions
BMS-986213, Nivolumab, XELOX, FOLFOX, SOX
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
13
States / cities
Clovis, California • Duarte, California • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Nov 3, 2026, 5:24 AM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

NCT01768559
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Lixisenatide (AVE0010), Insulin glulisine QD, Insulin glulisine TID, Insulin Glargine (Mandatory background drug), Metformin (Background drug)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
46
States / cities
Sun City, Arizona • Tempe, Arizona • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Nov 3, 2026, 5:24 AM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy Trial of Testosterone Undecanoate

NCT01765179
View directory record Official record
Conditions
Male Hypogonadism
Interventions
Oral testosterone undecanoate
Drug
Lead sponsor
Clarus Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
27
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Nov 3, 2026, 5:24 AM EST
Not listed Phase 2Phase 3 Interventional

Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation

NCT00691470
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter, Venous Thromboembolic Disease, Myocardial Infarction, Cardiomyopathy
Interventions
ATI-5923, Coumadin (warfarin)
Drug
Lead sponsor
ARYx Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2010 · Synced Nov 3, 2026, 5:24 AM EST